REG - Scancell Hlds - Scancell to Present at 2024 AACR Annual Meeting

Scancell HoldingsAnnouncement

02/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240402:nRSB8068Ia&default-theme=true

RNS Number : 8068I  Scancell Holdings Plc  02 April 2024

02 April 2024

 

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Scancell to Present at 2024 AACR Annual Meeting

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer, today announces that Professor Lindy Durrant will be
presenting at American Association for Cancer Research (AACR) Annual Meeting,
taking place in San Diego, California on 5-10 April 2024.

 

Scancell will present data on its open-label Phase 2 SCOPE trial,
investigating its cancer vaccine, SCIB1, in combination with checkpoint
inhibitors (CPIs) in advanced melanoma. SCIB1 previously demonstrated an 85%
response rate among 13 first-line advanced melanoma patients.

 

The AACR conference is an internationally recognized annual meeting, serving
as a focal point of the cancer research community where the latest advances in
the cancer space can be shared amongst world leading experts. Scancell is
presenting as part of the 'Cancer Vaccines: Ready for Prime Time?' clinical
trials symposium, covering progress from a number of innovative clinical stage
cancer vaccines, including follow up data from the BioNTech mRNA vaccine.

 

Presentation Details:

 

Title (https://www.abstractsonline.com/pp8/#!/20272/presentation/11402) : A
DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab +
ipilimumab in patients with advanced unresectable melanoma: Efficacy and
safety results from the open-label Phase 2 SCOPE Trial

Session (https://www.abstractsonline.com/pp8/#!/20272/session/663) : CTMS01 -
Cancer Vaccines: Ready for Prime Time?

Session Date and Time: Sunday 7 April 2024, 3:50 PM - 4:00 PM PST

Location: Ballroom 20 AB - Upper Level - Convention Center

Published Abstract Number: CT024

Speaker: Professor Lindy Durrant, Chief Executive Officer and Chief Scientific
Officer

Authors: H. Shaw, P. Patel, M. Payne, S. Kumar, M. Highley, K. Prasad, R.
Board, C. Barlow, S. Danson, R. Miller, G. Goodhew, F. Master, L. Durrant

 

 

-ENDS-

 

 For further information, please contact:

 Scancell Holdings plc                                                +44 (0) 20 3709 5700
 Professor Lindy Durrant, CEO

 Dr Jean-Michel Cosséry, Non-Executive Chairman

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)  +44 (0) 20 7710 7600
 Nicholas Moore/Samira Essebiyea (Healthcare Investment Banking)
 Nick Adams/Nick Harland (Corporate Broking)

 WG Partners LLP (Joint Broker)                                       +44 (0) 20 3705 9330
 David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby

 Panmure Gordon (UK) Limited (Joint Broker)                           +44 (0) 20 7886 2500
 Freddy Crossley/Emma Earl (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 

 ICR Consilium                                  +44 (0) 20 3709 5700
 Mary-Jane Elliott/Angela Gray/Lindsey Neville  scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

About the SCOPE Phase 2 clinical trial

 

SCOPE is an open label, multicohort, multicentre, Phase 2 study of SCIB1 in
patients with advanced unresectable melanoma receiving either nivolumab with
ipilimumab or pembrolizumab. SCIB1 is a deoxyribonucleic acid (DNA) plasmid
vaccine encoding two CD8 epitopes from the melanoma antigens
tyrosinase-related protein-2 and glycoprotein 100 (gp100), plus two CD4
epitopes from gp100. The purpose of the study is to determine whether the
addition of SCIB1 to standard of care CPIs can improve the objective response
rate (ORR) of patients with advanced melanoma relative to the CPIs alone. The
ORR is defined as the proportion of patients with a complete or partial
response at any time after the start of treatment. During the first stage of
the SCOPE trial reported here, patients received SCIB1 in combination with the
best treatment currently available, namely the CPIs nivolumab and ipilimumab.
The First Stage milestone was designed to demonstrate at least a 70% ORR with
an 80% power i.e. at least 9/15 patients responding, assessed by radiological
imaging. Further information relating to the clinical trial can be found on
the Company's website at https://www.scancell.co.uk
(https://www.scancell.co.uk) and at
 https://classic.clinicaltrials.gov/ct2/show/NCT04079166
(https://classic.clinicaltrials.gov/ct2/show/NCT04079166)

 

 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer. The Company is building a pipeline of innovative products by utilising
its four technology platforms: Moditope(®) and ImmunoBody(®) for vaccines
and GlyMab(®) and AvidiMab(®) for antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope(®) and
ImmunoBody(®)) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab(®)) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab(®)).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCJPMRTMTJTBRI